25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies

Key Takeaways Explain This Topic AI

A restrictive transfusion threshold (Hb <7.0 g/dL, targeting 7.0-8.0 g/dL) is the evidence-based standard for hemodynamically stable hospitalized adults, reducing nosocomial infections, volume overload, and all-cause mortality (TRICC, FOCUS, Villanueva trials); a liberal threshold (Hb <8.0 g/dL, target 8.0-10.0 g/dL) is strictly reserved for acute coronary syndromes, active myocardial ischemia, or uncontrolled hemorrhage.

Acute Hemolytic Transfusion Reaction (AHTR) is most commonly triggered by clerical identification error causing ABO incompatibility and intravascular complement-mediated lysis; immediate management requires stopping the infusion, vigorous IV hydration to maintain urine output >100-200 mL/h, and blood/urine return to the blood bank.

Transfusion-Related Acute Lung Injury (TRALI) is the leading cause of transfusion-related mortality, characterized by donor anti-HLA/anti-HNA antibodies causing non-cardiogenic pulmonary edema, fever, and hypotension within 6 hours (supportive care; avoid diuretics); whereas Transfusion-Associated Circulatory Overload (TACO) is hydrostatic volume overload with hypertension, elevated BNP, and rapid response to IV furosemide.

Thrombotic Thrombocytopenic Purpura (TTP) is caused by severe deficiency (<10%) of the vWF-cleaving metalloprotease ADAMTS13, producing microvascular platelet thrombi, severe consumptive thrombocytopenia, and microangiopathic hemolytic anemia (MAHA); emergent Therapeutic Plasma Exchange (TPE) and systemic corticosteroids are life-saving, whereas platelet transfusion is strictly contraindicated ('adding fuel to the fire').

Disseminated Intravascular Coagulation (DIC) represents systemic generation of thrombin and secondary hyperfibrinolysis leading to simultaneous thrombosis and hemorrhage; laboratory findings show prolonged PT/INR, prolonged aPTT, severe thrombocytopenia, fibrinogen <100 mg/dL, and elevated D-dimer, managed by treating the underlying trigger alongside cryoprecipitate (target fibrinogen >100-150 mg/dL), platelets, and FFP.

Last updated: September 2026

Severe Symptomatic Anemia: Pathophysiology & Clinical Assessment

Severe anemia presents across a clinical spectrum defined by the acuity of onset, the efficacy of cardiovascular and biochemical compensatory mechanisms, and the presence of underlying cardiopulmonary reserve. Understanding the physiological distinction between acute hemorrhagic blood loss and chronic compensatory anemia is essential for emergency stabilization and transfusion decision-making.

Acute Blood Loss vs. Chronic Compensatory Anemia

Acute Hemorrhagic Blood Loss :

Pathophysiology : The primary threat in acute hemorrhage is not the immediate loss of red blood cell mass, but the precipitous collapse of effective circulating intravascular volume leading to hypovolemic shock, diminished venous return (preload), reduced cardiac output, and inadequate tissue perfusion.

Diagnostic Pitfall : Initial hemoglobin and hematocrit values measured immediately following acute hemorrhage are deceptively normal. Because whole blood (plasma and erythrocytes in equal proportion) is lost simultaneously, the concentration of erythrocytes per unit volume of blood remains unchanged. A drop in hemoglobin and hematocrit only becomes evident 8 to 24 hours later, as transcapillary interstitial fluid shifts into the intravascular space and exogenous crystalloid resuscitation dilutes the remaining red blood cell mass.

Primary Clinical Focus : Rapid volume resuscitation with balanced crystalloids (e.g., lactated Ringer's) or immediate blood product activation (e.g., massive transfusion protocol using a 1:1:1 ratio of packed red blood cells, fresh frozen plasma, and platelets) to restore end-organ perfusion.

Chronic Compensatory Anemia :

Pathophysiology : When red cell mass declines gradually over weeks to months (e.g., chronic gastrointestinal bleeding, menorrhagia, nutritional deficiencies, chronic kidney disease), the body engages robust compensatory mechanisms to preserve tissue oxygenation despite profound reductions in hemoglobin (often down to 4.0-5.0 g/dL).

Cardiovascular Compensation : Sustained plasma volume expansion maintains total circulating volume. Cardiac output increases through increases in resting stroke volume and resting heart rate, coupled with reduced blood viscosity (which decreases systemic vascular resistance and left ventricular afterload).

Biochemical Compensation (Oxyhemoglobin Dissociation Curve) : Intraerythrocytic accumulation of 2,3-diphosphoglycerate (2,3-DPG) shifts the oxyhemoglobin dissociation curve to the right . This rightward shift decreases hemoglobin's affinity for oxygen, facilitating the offloading of oxygen from hemoglobin to peripheral tissues at higher capillary oxygen partial pressures.

Clinical Consequence : Patients with chronic severe anemia can walk into the clinic with hemoglobin levels of 4.5 g/dL reporting only mild exertional fatigue, whereas an acute drop of hemoglobin to 7.0 g/dL in a trauma patient produces diaphoresis, hypotension, and circulatory collapse.

Clinical Indicators of Hemodynamic Decompensation

Regardless of baseline chronicity, severe anemia can overwhelm compensatory capacity, resulting in critical tissue hypoxia and end-organ failure. The emergence of the following signs dictates urgent emergency department transfer and packed red blood cell (PRBC) transfusion:

Hemodynamic Instability : Resting tachycardia (>110 bpm), orthostatic vital sign changes (a systolic blood pressure drop ≥20 mmHg or pulse increase ≥20 bpm upon standing), or persistent resting hypotension (systolic BP <90 mmHg or mean arterial pressure <65 mmHg).

Myocardial Ischemia & Angina : Anemic patients with underlying coronary artery disease develop demand-supply mismatch (Type 2 Myocardial Infarction), presenting with angina pectoris, ischemic ST-segment depressions, T-wave inversions, or elevated cardiac troponins.

Cerebral Hypoperfusion : Lightheadedness, pre-syncope, syncope, confusion, lethargy, or altered mental status.

High-Output Heart Failure : Progressive exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, bibasilar pulmonary rales, jugular venous distension, S3 gallop, and peripheral pitting edema due to excessive cardiac workload attempting to meet peripheral oxygen demands.

Evidence-Based Transfusion Thresholds: Restrictive vs. Liberal Strategies

For decades, clinical dogma maintained that a hemoglobin level of 10.0 g/dL (or hematocrit of 30%) was the universal minimum safe threshold (the classic '10/30 rule'). Over the past two decades, rigorous multi-center randomized controlled trials have dismantled this concept, proving that liberal transfusion strategies increase complications without conferring clinical benefit. TRANSFUSION THRESHOLD PARADIGM

┌─────────────────────────────────────────────────────────────┐
│ RESTRICTIVE STRATEGY (Hb < 7.0 g/dL) │
├─────────────────────────────────────────────────────────────┤
│ • Hemodynamically stable hospitalized medical/ICU patients │
│ • Non-cardiac surgery patients │
│ • Acute upper gastrointestinal bleeding (Villanueva trial) │
│ • Target Post-Transfusion Hb: 7.0 - 8.0 g/dL │
│ • PROVEN BENEFITS: Reduced mortality, fewer infections, │
│ decreased pulmonary edema, lowered transfusion reactions │
└─────────────────────────────────────────────────────────────┘
vs
┌─────────────────────────────────────────────────────────────┐
│ LIBERAL STRATEGY (Hb < 8.0 g/dL) │
├─────────────────────────────────────────────────────────────┤
│ • Acute Coronary Syndromes (ACS) / Active Cardiac Ischemia │
│ • Pre-existing symptomatic cardiovascular disease undergoing │
│ major orthopedic/vascular surgery (FOCUS trial threshold) │
│ • Target Post-Transfusion Hb: 8.0 - 10.0 g/dL │
│ • Active, uncontrolled, life-threatening hemorrhage │
└─────────────────────────────────────────────────────────────┘
Landmark Clinical Trials Supporting Restrictive Transfusion

TRICC Trial (Transfusion Requirements in Critical Care, NEJM 1999) :

Enrolled 838 critically ill, euvolemic ICU patients randomized to a restrictive strategy (transfuse if Hb <7.0 g/dL, target 7.0-8.0 g/dL) versus a liberal strategy (transfuse if Hb <10.0 g/dL, target 10.0-12.0 g/dL).

Key Findings : 30-day mortality was lower in the restrictive group among patients who were less critically ill (APACHE II score ≤20) and younger (<55 years). Restrictive transfusion dramatically reduced exposure to allogeneic blood products without compromising organ recovery.

FOCUS Trial (Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair, NEJM 2011) :

Evaluated 2,016 elderly patients with high cardiovascular risk undergoing hip fracture surgery randomized to restrictive (transfuse for symptoms of anemia or Hb <8.0 g/dL) versus liberal (transfuse for Hb <10.0 g/dL).

Key Findings : No difference in mortality, functional recovery, or ambulatory ability at 60 days. A restrictive threshold of 8.0 g/dL is safe and effective in surgical patients with pre-existing cardiovascular disease.

Villanueva Trial (Transfusion Strategies for Upper Gastrointestinal Bleeding, NEJM 2013) :

Evaluated 921 patients with severe acute upper gastrointestinal bleeding randomized to restrictive (transfusion threshold Hb <7.0 g/dL, target 7.0-9.0 g/dL) versus liberal (threshold Hb <9.0 g/dL, target 9.0-11.0 g/dL).

Critical Board Result : Mortality at 45 days was significantly lower in the restrictive group (5% vs. 9%, p=0.02) . The restrictive strategy also significantly reduced the rate of further bleeding (10% vs. 16%) and systemic adverse events. The physiological mechanism is that aggressive liberal transfusion increases portal and systemic pressures, dislodging early hemostatic clots and precipitating rebleeding.

Transfusion Dosing Principles

In a non-bleeding, hemodynamically stable adult of average size (~70 kg), one unit of packed red blood cells (PRBCs) increases the circulating hemoglobin by approximately 1.0 g/dL and the hematocrit by approximately 3% .

The modern standard of care mandates a 'single-unit transfusion strategy' : administer one single unit of PRBCs, reassess the patient clinically, and recheck the hemoglobin level prior to ordering additional units. Routine ordering of '2 units of PRBCs' for stable inpatients is obsolete and increases the risk of Transfusion-Associated Circulatory Overload (TACO).

Acute Transfusion Reactions: Master Differential & Emergency Management

Acute transfusion reactions occur during or within 24 hours of blood product administration. When an adverse reaction occurs, immediate systematic recognition and differentiation are paramount.

Comprehensive Diagnostic & Management Matrix

Reaction Type Primary Pathophysiology Clinical Presentation Key Diagnostic Findings Immediate Emergency Action Prevention

Acute Hemolytic Transfusion Reaction (AHTR) ABO incompatibility (clerical error); preformed recipient IgM antibodies bind donor RBC antigens, triggering complement cascade and intravascular hemolysis Fever, chills, flank/back pain , dyspnea, flushing, chest tightness, red/brown urine, progressing to hypotension, DIC, and acute renal failure + Direct Antiglobulin Test (DAT/Coombs); pink/red plasma (free Hb); elevated indirect bilirubin and LDH; undetectable haptoglobin; hemoglobinuria STOP transfusion immediately ; maintain IV access with normal saline; aggressive hydration (maintain UOP >100-200 mL/h); send blood/urine to blood bank; treat shock/DIC Strict double-checking of patient and blood unit identifiers at the bedside

Febrile Non-Hemolytic Transfusion Reaction (FNHTR) Recipient anti-leukocyte antibodies react against donor white blood cells; or infusion of inflammatory cytokines (IL-1, IL-6, TNF-alpha) accumulated during storage Temperature elevation ≥1°C (≥1.8°F) above baseline (typically within 1-6 hours); chills, rigors, headache; blood pressure remains normal Negative DAT/Coombs; no evidence of hemolysis (normal LDH, haptoglobin, bilirubin); rule out sepsis and AHTR Stop transfusion temporarily to evaluate; administer Acetaminophen (650-1000 mg PO) ; meperidine for severe rigors; resume if hemolysis excluded and symptoms abate Pre-storage leukoreduction of blood products (reduces FNHTR rates by >90%)

Allergic / Urticarial Reaction Recipient IgE antibodies react against soluble donor plasma proteins, triggering mast cell and basophil histamine release Localized or generalized pruritus, urticaria (hives), erythema, cutaneous flushing; no systemic signs, no airway compromise, no hypotension Negative DAT; normal vitals aside from pruritus; clinical diagnosis Pause transfusion ; administer Diphenhydramine 25-50 mg IV/PO ; if symptoms resolve and no systemic signs develop within 30 min, transfusion may be cautiously resumed Premedication with antihistamines if history of recurrent allergic reactions

Anaphylactic Reaction Severe IgE-mediated or anti-IgA antibody-mediated response in an IgA-deficient recipient receiving IgA-containing plasma Sudden onset within seconds to minutes of initiating transfusion: urticaria, angioedema, stridor, wheezing, severe dyspnea, gastrointestinal cramping, shock Negative DAT; absent IgA levels in recipient serum with anti-IgA antibodies; hypotension and bronchospasm STOP transfusion immediately; DO NOT RESTART ; administer Epinephrine 0.3-0.5 mg IM (1:1,000) into anterolateral thigh; IV crystalloid bolus; airway support; diphenhydramine and methylprednisolone Washed RBC products (removes residual donor plasma) or blood products from verified IgA-deficient donors

Transfusion-Related Acute Lung Injury (TRALI) Donor antibodies (anti-HLA Class I/II or anti-HNA) bind recipient neutrophils sequestered in pulmonary microvasculature; causes neutrophil activation, endothelial damage, capillary leak, and non-cardiogenic pulmonary edema Hypoxemia (SpO2 <90% on room air or PaO2/FiO2 ≤300), bilateral crackles, tachypnea, acute dyspnea, fever, and hypotension developing within 6 hours of transfusion Bilateral fluffy alveolar/interstitial infiltrates on chest radiograph; normal cardiac silhouette; normal or low BNP (<250 pg/mL) ; normal CVP/PCWP; no jugular venous distension STOP transfusion immediately ; aggressive supportive respiratory care (supplemental O2, non-invasive ventilation, or low-tidal-volume mechanical ventilation); AVOID DIURETICS (worsens hypotension) Defer multiparous female plasma donors (high anti-HLA antibody prevalence); use predominantly male plasma

Transfusion-Associated Circulatory Overload (TACO) Hydrostatic cardiogenic pulmonary edema caused by excessive volume or rapid infusion rate exceeding cardiac compliance; common in elderly, renal failure, or baseline heart failure Severe dyspnea, tachypnea, orthopnea, cough producing pink frothy sputum, systolic hypertension (pulse pressure wide) , tachycardia, jugular venous distension, S3 gallop within 6 hours Bilateral interstitial edema, cardiomegaly, Kerley B lines on CXR; markedly elevated BNP / NT-proBNP (>1.5x baseline) ; elevated CVP; afebrile STOP transfusion immediately ; sit patient fully upright; high-flow oxygen; administer IV Furosemide (20-40 mg IV) ; venodilators (nitroglycerin) if refractory hypertension Transfuse single units slowly (over 3-4 hours per unit); administer prophylactic IV furosemide between units in high-risk patients

Detailed Emergency Protocols for Transfusion Reactions
Immediate Universal Transfusion Reaction Protocol

Whenever a patient exhibits fever, chills, dyspnea, back pain, urticaria, or vital sign instability during a blood transfusion:

Stop the transfusion immediately . Disconnect the blood administration tubing completely from the patient's intravenous catheter. Do not flush the tubing containing remaining donor blood into the patient.

Aspirate and flush the IV catheter with sterile normal saline to maintain reliable intravenous access.

Assess Airway, Breathing, Circulation, and Vital Signs : Immediately check for stridor, wheezing, hypotension, or hypoxemia.

Clerical Verification : Check the patient's wristband against the blood product unit label to verify ABO/Rh compatibility and correct patient identification.

Laboratory Notification & Return : Return the unused blood unit, attached tubing, and blood administration set to the blood bank. Send post-transfusion recipient blood tubes (EDTA lavender-top and plain red-top) and a newly voided urine specimen to the laboratory for:

Repeat ABO and Rh typing and crossmatch;
Direct Antiglobulin Test (DAT / Coombs test);

Visual inspection of post-transfusion plasma for pink/red discoloration (free hemoglobin from intravascular hemolysis);

Complete blood count, serum LDH, indirect bilirubin, haptoglobin, and coagulation studies (PT/INR, aPTT, fibrinogen);

Urinalysis for free hemoglobinuria.

TRALI vs. TACO: Critical Board Discrimination

TRALI and TACO represent the two leading causes of transfusion-related mortality. Both present within 6 hours of transfusion with acute hypoxemic respiratory failure and bilateral pulmonary infiltrates. Correctly differentiating between them is a high-yield board competency because their medical therapies are diametrically opposed: TRALI versus TACO COMPARISON

CLINICAL FEATURE TRALI TACO
───────────────────────────────────────────────────────────────────
Pathophysiology Non-cardiogenic capillary Cardiogenic hydrostatic
leak (neutrophil-mediated) volume overload
Blood Pressure Hypotension (or normal) Hypertension (systolic surge)
Body Temperature Fever (often >38°C) Typically afebrile (normal)
Jugular Veins / CVP Normal or flat / low CVP Elevated JVD / high CVP
Cardiac Auscultation No gallop, normal S1/S2 S3 gallop present
BNP / NT-proBNP Normal or mildly elevated Markedly elevated (>1.5x)
Pulmonary Edema Fluid Exudative (high protein) Transudative (low protein)
Fluid Balance Normal or depleted Severely positive
Response to Diuretics Ineffective; causes severe Rapid, dramatic improvement
hypotensive collapse in oxygenation and dyspnea
Core Treatment Low-tidal mechanical vent, Upright posture, O2, IV
IV fluids for hypotension Furosemide 20-40 mg

Critical Exam Pearl : Transfusion-Related Acute Lung Injury is treated like Acute Respiratory Distress Syndrome (ARDS) with lung-protective ventilation and judicious fluid resuscitation if hypotensive. Administering loop diuretics to a patient with TRALI depletes intravascular volume, precipitating profound circulatory shock. In contrast, Transfusion-Associated Circulatory Overload requires aggressive diuresis with IV furosemide.

Life-Threatening Coagulopathic Emergencies
Thrombotic Thrombocytopenic Purpura (TTP)

Thrombotic Thrombocytopenic Purpura is a fulminant, life-threatening hematologic emergency with a historical mortality exceeding 90% if untreated, which decreases to <15% with prompt recognition and emergency Therapeutic Plasma Exchange (TPE). TTP PATHOPHYSIOLOGY CASCADE

Autoantibodies (IgG) against ADAMTS13 Metalloprotease
│
▼
Severe ADAMTS13 Enzyme Deficiency (<10% Activity)
│
▼
Failure to Cleave Ultra-Large von Willebrand Factor Multimers
│
▼
Spontaneous Platelet Adhesion & Microvascular Thrombosis
│
┌─────────────────────────┴─────────────────────────┐
▼ ▼
Microvascular Occlusion & Ischemia Severe Platelet Consumption
(Brain, Kidney, Heart) (Thrombocytopenia <30,000/uL)
│ │
▼ ▼
RBC Shearing (MAHA / Schistocytes) Mucocutaneous Bleeding (Purpura)
Pathophysiology & Molecular Mechanism

Under physiological conditions, endothelial cells synthesize and release ultra-large von Willebrand factor (ULvWF) multimers. The plasma zinc metalloprotease ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) specifically cleaves these reactive multimers into smaller, less adhesive fragments.

In acquired (autoimmune) TTP , circulating IgG autoantibodies neutralize or clear ADAMTS13, resulting in severe enzyme deficiency (<10% normal activity).

Uncleaved ULvWF multimers bind avidly to platelet glycoprotein Ib/IX receptors, initiating spontaneous, widespread platelet aggregation and the formation of rich microvascular platelet-vWF thrombi throughout the microcirculation.

These microthrombi produce mechanical shearing of passing erythrocytes—generating fragmented red cells ( schistocytes or 'helmet cells') and intravascular hemolysis—while simultaneously causing end-organ tissue ischemia.

Clinical Presentation: The Diagnostic Pentad

The classic pentad of TTP includes:

Microangiopathic Hemolytic Anemia (MAHA) : Intravascular hemolysis with abundant schistocytes on peripheral blood smear (typically >1-2% of RBCs), marked indirect hyperbilirubinemia, elevated serum LDH (>1000 U/L), and low/undetectable serum haptoglobin with a negative direct antiglobulin (Coombs) test.

Severe Thrombocytopenia : Marked reduction in circulating platelets, typically <20,000 to 30,000/µL , resulting in petechiae, purpura, ecchymoses, epistaxis, or gingival bleeding.

Fluctuating Neurologic Symptoms : Present in over 60% of cases; characteristically waxing and waning due to transient cerebral microthrombosis. Manifestations range from mild headache, confusion, and expressive aphasia to focal motor deficits, seizures, and coma.

Renal Dysfunction : Usually mild to moderate (elevated serum creatinine, microscopic hematuria, mild proteinuria); acute anuric renal failure is uncommon in TTP (which distinguishes it from Hemolytic Uremic Syndrome).

Fever : Present in approximately 20-30% of cases, typically low-grade.

Critical Clinical Caveat : The complete pentad is present in fewer than 5% to 10% of patients at initial presentation. Modern diagnostic criteria mandate that the presence of unexplained MAHA and thrombocytopenia alone (the dyad) , in the absence of an alternative diagnosis (such as DIC or severe sepsis), is sufficient to establish a presumptive diagnosis and trigger emergency therapy.

Diagnostic Confirmation

ADAMTS13 Activity Level : Diagnostic confirmation requires demonstrating ADAMTS13 activity <10% (normal: 67-150%). An ADAMTS13 inhibitor (autoantibody) assay should be obtained concurrently.

Management Mandate : Blood samples for ADAMTS13 testing must be drawn prior to initiating plasma exchange , but treatment must NEVER be delayed while awaiting the ADAMTS13 test result (which often requires several days to return from reference laboratories).

Coagulation Studies : Routine coagulation parameters— PT/INR, aPTT, and fibrinogen—are characteristically NORMAL in isolated TTP . This is a pivotal board differentiator from Disseminated Intravascular Coagulation (DIC), where coagulation factors are consumed and PT/aPTT are prolonged.

Emergency Therapeutic Management

Therapeutic Plasma Exchange (TPE / Plasmapheresis) :

The absolute cornerstone of therapy. TPE must be initiated on an emergent basis (within 4 to 8 hours of clinical suspicion).

Mechanisms : Removes circulating IgG anti-ADAMTS13 autoantibodies, removes ultra-large vWF multimers, and infuses functional ADAMTS13 enzyme present in donor plasma.

Regimen : 1.0 to 1.5 plasma volume exchange daily using fresh frozen plasma or solvent-detergent treated plasma until platelet count recovers to >150,000/µL and LDH normalizes for at least two consecutive days.

Bridging : If TPE is delayed due to vascular access placement or transfer logistics, infuse Fresh Frozen Plasma (15-30 mL/kg IV) to provide exogenous ADAMTS13 until TPE can begin.

Systemic Corticosteroids :

High-dose corticosteroids suppress anti-ADAMTS13 autoantibody production: Methylprednisolone 1,000 mg IV daily for 3 days , followed by oral Prednisone 1 mg/kg/day with a gradual taper.

Caplacizumab (Anti-vWF Nanobody) :

A bivalent humanized variable-domain immunoglobulin fragment that specifically targets the A1 domain of vWF, blocking its interaction with platelet glycoprotein Ib receptors. Administered as an initial 10 mg IV bolus prior to first TPE, followed by 10 mg subcutaneous daily. Accelerates platelet recovery and dramatically reduces thromboembolic complications and refractory disease.

Rituximab (Anti-CD20 Monoclonal Antibody) :

Administered (375 mg/m² IV weekly x 4 doses) in acute autoimmune TTP to eradicate B-cell clones producing anti-ADAMTS13 antibodies, reducing relapse rates.

The Critical Platelet Transfusion Contraindication

PLATELET TRANSFUSIONS ARE STRICTLY CONTRAINDICATED IN TTP .

Transfusing exogenous platelets into a patient with active TTP provides immediate substrate for ultra-large vWF multimers, exacerbating microvascular thrombosis. This phenomenon—colloquially termed 'adding fuel to the fire' —has precipitated acute stroke, acute myocardial infarction, cardiovascular collapse, and immediate death.

Platelet transfusion is reserved solely for patients with catastrophic, immediately life-threatening active hemorrhage (e.g., symptomatic intracranial hemorrhage).

Disseminated Intravascular Coagulation (DIC)

Disseminated Intravascular Coagulation is a secondary clinicopathologic syndrome characterized by the systemic, uncontrolled activation of coagulation, resulting in diffuse microvascular fibrin deposition (thrombosis) and the simultaneous consumption of platelets and clotting factors (consumptive coagulopathy and severe bleeding). DIC PATHOPHYSIOLOGIC PARADOX

Systemic Trigger (Sepsis, Trauma, Malignancy, Obstetric)
│
▼
Massive Tissue Factor (TF) Exposure & Release
│
▼
Uncontrolled Thrombin Generation
│
┌─────────────────────────┴─────────────────────────┐
▼ ▼
DIFFUSE MICROVASCULAR THROMBOSIS CONSUMPTIVE COAGULOPATHY
Fibrin deposition in arterioles • Severe Platelet Depletion
Microvascular shear (Schistocytes) • Clotting Factor Consumption
Multi-Organ Dysfunction Syndrome (I, II, V, VIII, X depleted)
(AKI, Liver, ARDS, Encephalopathy) • Secondary Hyperfibrinolysis
│
▼
UNCONTROLLED PROFUSE BLEEDING
(IV sites, incisions, mucosa)
Pathophysiology & Etiologic Triggers

DIC is never a primary disease; it is always provoked by an underlying condition that introduces procoagulant materials into the circulation:

Sepsis and Severe Infection (46%) : Bacterial endotoxins (lipopolysaccharide from Gram-negative bacilli) and inflammatory cytokines (IL-1, IL-6, TNF-alpha) cause massive endothelial expression of Tissue Factor (TF) and downregulate natural anticoagulant pathways (Protein C, Protein S, Antithrombin III).

Severe Trauma & Burns : Extensive crush injury, neurotrauma (release of brain thromboplastin), and hypothermia/acidosis.

Obstetric Catastrophes : Placental abruption, amniotic fluid embolism (rich in tissue factor), retained dead fetus syndrome, and preeclampsia/HELLP syndrome.

Malignancy : Acute Promyelocytic Leukemia (APL / AML M3, where malignant promyelocytes express high levels of tissue factor and annexin II, producing hyperfibrinolytic DIC) and metastatic adenocarcinomas (pancreas, prostate, lung).

Laboratory Diagnostic Profile

The hallmark of DIC is the simultaneous depletion of clotting factors and excessive fibrin turnover:

Prolonged Prothrombin Time (PT/INR) and activated Partial Thromboplastin Time (aPTT) : Caused by consumptive exhaustion of plasma coagulation factors (Fibrinogen, Prothrombin, Factors V, VIII, and X).

Severe Thrombocytopenia : Typically <50,000 to 100,000/µL due to continuous platelet incorporation into widespread microvascular thrombi.

Marked Hypofibrinogenemia : Plasma fibrinogen levels fall severely (<100 mg/dL). Fibrinogen is an acute-phase reactant; a 'low-normal' fibrinogen in a septic, critically ill patient reflects active consumptive depletion.

Markedly Elevated Fibrin Degradation Products (FDPs) and D-Dimer : Excessive secondary plasmin generation breaks down crosslinked fibrin mesh, generating D-dimer levels often >10-20 times the upper limit of normal.

Peripheral Blood Smear : Demonstrates moderate schistocytes (fragmented RBCs) in approximately 50% of cases, reflecting mechanical erythrocyte disruption across intravascular fibrin mesh.

Differential Diagnosis of Microangiopathic & Consumptive Thrombocytopenias

Diagnostic Feature Thrombotic Thrombocytopenic Purpura (TTP) Disseminated Intravascular Coagulation (DIC) Hemolytic Uremic Syndrome (HUS) Immune Thrombocytopenia (ITP)

Primary Mechanism ADAMTS13 deficiency; ultra-large vWF multimers Systemic thrombin generation; factor/platelet consumption Shiga toxin (STEC); glomerular endothelial injury Anti-platelet autoantibodies (GpIIb/IIIa clearance)

Platelet Count Severely decreased (<20,000-30,000/µL) Severely decreased (<50,000/µL) Severely decreased (<30,000-50,000/µL) Severely decreased (<20,000/µL)

PT / INR & aPTT NORMAL PROLONGED (both PT and aPTT) NORMAL NORMAL
Fibrinogen Normal or elevated Severely Depleted (<100 mg/dL) Normal or elevated Normal
D-Dimer / FDPs Normal or mildly elevated Markedly Elevated Normal or mildly elevated Normal

Peripheral Smear Prominent Schistocytes (frequently >2-5%) Variable Schistocytes (~50% of cases) Prominent Schistocytes Normal RBC morphology; giant platelets

Renal Impairment Mild to moderate azotemia Part of multi-organ failure Severe Oliguric / Anuric AKI None
Neurologic Signs Prominent, fluctuating (60%) Mild / late (due to shock/hypoxia) Rare / mild Absent

Primary Treatment Emergent TPE + Steroids + Caplacizumab Treat underlying cause; Cryoprecipitate, FFP, Platelets Supportive care; eculizumab (if atypical) Steroids, IVIG, Anti-D, TPO receptor agonists

Emergency Supportive Hemostatic Management

Treat the Underlying Cause : DIC cannot be arrested without eliminating the primary trigger: broad-spectrum antibiotics and surgical source control for sepsis, immediate evacuation/delivery of the uterus for placental abruption, stabilization of trauma, or all-trans retinoic acid (ATRA) for acute promyelocytic leukemia.

Blood Product Replacement Protocol (Indicated for Active Hemorrhage or Invasive Procedures) :

Cryoprecipitate : The single most effective product to replete fibrinogen. Administer 10 units (1 to 2 pools) of cryoprecipitate to maintain plasma fibrinogen >100 to 150 mg/dL (target >150-200 mg/dL in severe obstetric hemorrhage).

Platelet Transfusion : Transfuse pooled or apheresis platelets to maintain a platelet count >50,000/µL in the presence of active bleeding or prior to urgent surgical procedures (maintain >20,000/µL in non-bleeding patients at high risk of hemorrhage).

Fresh Frozen Plasma (FFP) : Indicated for active bleeding in the setting of prolonged PT/INR (>1.5) or prolonged aPTT. Standard dosing is 15 to 30 mL/kg IV (typically 3 to 4 units in an adult).

Packed Red Blood Cells (PRBCs) : Administer to restore oxygen-carrying capacity, maintaining hemoglobin >7.0 to 8.0 g/dL.

Role of Anticoagulation (Heparin) : Routine heparin is contraindicated in acute bleeding DIC. Low-dose intravenous unfractionated heparin (5-10 units/kg/h) is considered only in predominant prothrombotic phenotypes without active hemorrhage, such as purpura fulminans, retained dead fetus syndrome, or extensive acral ischemic gangrene.